Structure Therapeutics reported that their daily obesity pill resulted in a 16% weight loss relative to placebo after 44 weeks in Phase 2 trials, positioning them to compete against Eli Lilly and Novo Nordisk in developing oral GLP-1 treatments. This significant result outperforms recent competitors like Lilly's orforglipron, which showed only an 11% weight loss, highlighting the potential for Structure Therapeutics' pill in the obesity treatment market.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
2
Comments
Ali NematiWritten by Ali
